2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer

Wilfried E E Eberhardt, Dirk De Ruysscher, Walter Weder, Cecile Le Péchoux, Paul De Leyn, H. Hoffmann, Virginie Westeel, Rolf Stahel, Enriqueta Felip, Solange Peters, Keith Kerr, Benjamin Besse, Johan Vansteenkiste, Martin Edelman, Tony Mok, Ken O'Byrne, Silvia Novello, Lukas Bubendorf, Antonio Marchetti, Paul BaasMartin Reck, Konstantinos Syrigos, Luis Paz-Ares, Egbert F. Smit, Peter Meldgaard, Alex Adjei, Marianne Nicolson, Lucio Crinò, Paul Van Schil, Suresh Senan, Corinne Faivre-Finn, Gaetano Rocco, Giulia Veronesi, Jean Yves Douillard, Eric Lim, Christophe Dooms

Research output: Contribution to journalArticlepeer-review

Abstract

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on locally advanced disease.

Original languageEnglish
Pages (from-to)1573-1588
Number of pages16
JournalAnnals of Oncology
Volume26
Issue number8
DOIs
Publication statusPublished - 2015

Keywords

  • ESMO
  • Locally advanced
  • Non-small-cell lung cancer
  • Recommendations
  • Stage III

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint Dive into the research topics of '2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this